Researchers examined how sex interacts with genetic disease burden to influence clinical symptoms and brain changes in Huntington disease.

Ulixacaltamide is a highly selective small molecule T-type calcium channel inhibitor designed to block neuronal bursting in the cerebello-thalamo-cortical circuit linked to tremor activity.

Researchers assessed global trends in early-onset Parkinson Disease, focusing on incident cases, prevalence, years lived with disability, and disability-adjusted life years.

Researchers assessed the long-term outcomes of subthalamic stimulation for the treatment of Parkinson disease.

Researchers assessed signs and symptoms of prodromal Parkinson disease in community-dwelling older adults.

Researchers examined the association between incident PD in US Medicare beneficiaries aged 67 years and older in 2016 to 2018 and their residential exposure to ambient TCE in 2002.

After 36 months, patients treated with high dose AMT-130 saw a 75% slowing of disease progression vs the external control.

Researchers examined associations between PM2.5 exposure, dementia severity, and dementia-associated neuropathologic change.

Researchers conducted a prospective cohort study involving adults without PD aged 37 to 73 years from the UK Biobank to examine the association of MetS and its components with the risk for PD.

Researchers evaluated melatonin’s effects on sleep outcomes in patients with Parkinson disease.

Researchers assessed the relationship between Parkinson Disease risk and proximity to golf courses in a case-control study.

Researchers conducted a longitudinal, observational cohort study using data from the Parkinson’s Progression Markers Initiative.

Researchers trained 2 dogs to distinguish between dry skin swabs obtained from PwP and controls.

In a nationwide population-based prospective cohort study, researchers examined the association between autism spectrum disorder and the risk for Parkinson disease.

A phase 1 trial, LUMINA, is currently underway and is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in approximately 48 patients with ALS.

Researchers developed life course exposure measures for cyanobacteria and examined the association with survival in individuals with ALS.

In a longitudinal study, researchers assessed the association between long-term ultraprocessed food consumption and nonmotor features suggestive of prodromal Parkinson disease.

In a single-arm, open-label study, researchers assessed the safety and tolerability of psilocybin therapy in patients with Parkinson disease.

A regulatory decision is expected in the fourth quarter of 2025.

Researchers examined the association between ASD and future PD risk in a nationwide, population-based prospective cohort study.

In a modeling study, researchers estimated the age-, sex-, and year-specific global prevalence of Parkinson disease in 2050.

Researchers examined the association between long-term UPF consumption and nonmotor features suggestive of prodromal PD in a longitudinal analysis of participants from the Nurses’ Health Study and Health Professionals Follow-Up Study.

Researchers evaluated the association of treatment with antihypertensives, nonsteroidal anti-inflammatories (NSAIDs), and statins, as well as smoking and family history of PD with age at onset (AAO) of clinical symptoms.

Researchers conducted a modeling study to predict the global, regional, and national prevalence of Parkinson disease by age, sex, year, and Sociodemographic Index to 2050.

Investigators conducted a head-to-head comparison of 4 different technologies and 3 serum analytes to assess diagnostic and prognostic performance of NfL, glial fibrillary acidic protein (GFAP), and phosphorylated tau 181 (pTau181) biomarkers in ALS.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.